Suppliers / Corden Pharma

Corden Pharma

France reconciled across 30 public records · 18 entities Updated 9 July 2026

Corden Pharma is an API manufacturer based in France. It holds 17 active US drug master files and 3 valid CEPs across a filed portfolio of 17 molecules. Its filings concentrate with US FDA, MINSA (CR) and NAFDAC (NG). Its GMP standing is certified by ANSM (FR), EMA and ZLG (DE), among 9 authorities. Its most recent recorded inspection, by US FDA, closed on 14 November 2025 as NAI.

17
active US DMFs
3
valid CEPs
28
registered plants 8 with an FDA FEI number
34
filings across 10 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
5 of 5 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 14 November 2025 NAI US FDA
  • 14 February 2025 VAI US FDA
  • 14 June 2024 VAI US FDA
  • 3 February 2023 VAI US FDA
  • 14 September 2022 VAI US FDA
  • 21 April 2022 VAI US FDA
  • 18 March 2022 VAI US FDA
  • 13 September 2019 VAI US FDA
  • 6 February 2019 VAI US FDA
  • 2 November 2018 NAI US FDA
  • 27 September 2018 VAI US FDA
  • 6 July 2018 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Plankstadt, United Arab Emirates Not on file
Caponago, United Arab Emirates Not on file
Landen, Belgium Not on file
Bruxelles, Belgium Not on file
Landen, Belgium Not on file
VILLARS-SUR-GLÂNE, Switzerland Not on file

22 further sites are on record.

What they file, and where

Molecule Regulators Docs
Fenofibrate SFDA (Saudi Arabia), US FDA 3
Metronidazole EDQM, US FDA 3
Benzoyl Peroxide SFDA (Saudi Arabia), US FDA 2
Linaclotide SFDA (Saudi Arabia), US FDA 2
Paclitaxel EDQM, US FDA 2
1 US FDA 1
Bisoprolol US FDA 1
Bufexamac PMDA (Japan) 1
Choline Salicylate US FDA 1
Disulfiram US FDA 1
Show all 17 molecules on file
Ganciclovir SFDA (Saudi Arabia) 1
Nebivolol US FDA 1
Oxybutynin US FDA 1
Secnidazole US FDA 1
Tetrabenazine US FDA 1
Tirzepatide SFDA (Saudi Arabia) 1
Valganciclovir US FDA 1

Also appears on these molecule pages

Bisoprolol API Fenofibrate API Nebivolol API Oxybutynin API Tetrabenazine API

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA 12 3
MINSA (CR) 5 None
NAFDAC (NG) 4 1
DIGEMAPS (DO) 4 None
ARCSA (EC) 3 None
INVIMA (CO) 2 None
ANSM (FR) None 17
EMA None 16
ZLG (DE) None 10
ANVISA (Brazil) None 9
EDQM None 3
NCELS (KZ) None 2
INFARMED (PT) None 2

Questions about Corden Pharma

Does Corden Pharma hold a US DMF or a CEP?
Corden Pharma holds 17 active US drug master files and 3 valid CEPs. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Corden Pharma FDA-registered?
8 sites operated by Corden Pharma carry an FDA establishment identifier (FEI), which means they are registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Corden Pharma's last inspection go?
The most recent inspection on record closed on 14 November 2025 as NAI (No Action Indicated: nothing objectionable was found). 24 inspections are on file.
Where does Corden Pharma manufacture?
28 registered sites are on record, in United Arab Emirates, Belgium, Switzerland and Germany (Plankstadt, Caponago and Landen among others). Every site is listed on this page with the register it came from.
What does Corden Pharma make?
17 molecules are on record against Corden Pharma, including Fenofibrate, Metronidazole, Benzoyl Peroxide and Linaclotide. Each links through to that molecule's full manufacturer list.
Which regulators recognise Corden Pharma's GMP?
Current GMP certificates are on record from ANSM (FR), EMA, ZLG (DE), ANVISA (Brazil), US FDA and 4 more. GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Corden Pharma comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 14 November 2025.

Comparable suppliers

Hetero shares 3 molecules Piramal Pharma shares 3 molecules Harman Finochem shares 3 molecules Apitoria Pharma shares 2 molecules Olon shares 2 molecules

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates